Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
40
ACXP Quote, Financials, Valuation and Earnings
Last price:
$0.42
Seasonality move
:
-7.13%
Day range:
$0.42 - $0.44
52-week range:
$0.30 - $3.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
15.41x
Volume:
199.7K
Avg. volume:
139K
1-year change:
-80.45%
Market cap:
$9.5M
Revenue:
--
EPS (TTM):
-$0.87
Analysts' Opinion
-
Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.70, Acurx Pharmaceuticals has an estimated upside of 1457.56% from its current price of $0.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.43.
Fair Value
-
According to the consensus of 1 analyst, Acurx Pharmaceuticals has 1457.56% upside to fair value with a price target of $6.70 per share.
ACXP vs. S&P 500
-
Over the past 5 trading days, Acurx Pharmaceuticals has overperformed the S&P 500 by 10.24% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Acurx Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Acurx Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Acurx Pharmaceuticals reported revenues of --.
Earnings Growth
-
Acurx Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Acurx Pharmaceuticals reported earnings per share of -$0.16.
Enterprise value:
5.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.1M | -$14.6M | -$14.1M | -$5.1M | -$2.8M | |
| EBITDA | -$12.1M | -$14.6M | -$14.1M | -$5.1M | -$2.8M | |
| Diluted EPS | -$1.12 | -$1.15 | -$0.87 | -$0.38 | -$0.16 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | |
| Total Assets | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | |
| Current Liabilities | $472.6K | $843.9K | $2.1M | $3M | $3.2M | |
| Total Liabilities | $522.4K | $843.9K | $2.1M | $3M | $3.2M | |
| Total Equity | $2.7M | $12.4M | $7.3M | $4.7M | $615.1K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.5M | -$9.8M | -$10.4M | -$4.2M | -$2.3M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $8.2M | $6.6M | $4.6M | $194.6K | |
| Free Cash Flow | -$7.5M | -$9.8M | -$10.4M | -$4.2M | -$2.3M | |
ACXP
Sector
Market Cap
$9.5M
$34.9M
Price % of 52-Week High
12.93%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-80.46%
-38.5%
Beta (5-Year)
--
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.40
200-day SMA
Sell
Level
$1.32
Bollinger Bands (100)
Sell
Level
0.44 - 0.86
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Buy
Level
$0.37
Relative Strength Index (RSI14)
Buy
Level
55.45
ADX Line
Buy
Level
26.14
Williams %R
Sell
Level
-10.0925
50-day SMA
Sell
Level
$0.48
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
7.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company’s segment consists of the development of clinical and preclinical product candidates for the development of the Company’s proprietary new therapies.
Stock Forecast FAQ
In the current month, ACXP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACXP average analyst price target in the past 3 months is $6.70.
-
Where Will Acurx Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Acurx Pharmaceuticals share price will rise to $6.70 per share over the next 12 months.
-
What Do Analysts Say About Acurx Pharmaceuticals?
Analysts are divided on their view about Acurx Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Acurx Pharmaceuticals is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Acurx Pharmaceuticals's Price Target?
The price target for Acurx Pharmaceuticals over the next 1-year time period is forecast to be $6.70 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACXP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Acurx Pharmaceuticals is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ACXP?
You can purchase shares of Acurx Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Acurx Pharmaceuticals shares.
-
What Is The Acurx Pharmaceuticals Share Price Today?
Acurx Pharmaceuticals was last trading at $0.42 per share. This represents the most recent stock quote for Acurx Pharmaceuticals. Yesterday, Acurx Pharmaceuticals closed at $0.43 per share.
-
How To Buy Acurx Pharmaceuticals Stock Online?
In order to purchase Acurx Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
53
EAT alert for May 1
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
